The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

ADM Opens More Than $30 Million State-of-the-Art Production Facility in Spain
Finance

ADM Opens More Than $30 Million State-of-the-Art Production Facility in Spain

FEB 8, 2023
Call for Experts – A Survey on Microbiome-Based Biomarker Development
Pharma & Human Health

Call for Experts – A Survey on Microbiome-Based Biomarker Development

FEB 7, 2023
MD Anderson and Federation Bio to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers
Oncology

MD Anderson and Federation Bio to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers

FEB 2, 2023
“Probiotics” Green-lit for market-usage by French Authorities
Biotics and Supplements

“Probiotics” Green-lit for market-usage by French Authorities

JAN 25, 2023
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101
Clinical & Manufacturing

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101

JAN 24, 2023
New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits
Clinical & Manufacturing

New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits

JAN 24, 2023
World’s First Computational Reconstruction of a Virus in its Biological Entirety
Infectious Disease & AMR

World’s First Computational Reconstruction of a Virus in its Biological Entirety

JAN 23, 2023
IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections
Biotics and Supplements

IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections

JAN 16, 2023
Micronoma receives FDA breakthrough device designation for novel liquid biopsy assay for lung carcinoma detection
Oncology

Micronoma receives FDA breakthrough device designation for novel liquid biopsy assay for lung carcinoma detection

JAN 12, 2023
Microbiome Drug Development: 2022 in Review
Editor's Choice

Microbiome Drug Development: 2022 in Review

DEC 30, 2022
Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals
Editor's Choice

Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals

DEC 22, 2022